Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.35 Consensus Target Price from Analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.35.

A number of analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 price objective on the stock. BMO Capital Markets started coverage on Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. BTIG Research started coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $35.00 target price for the company. Oppenheimer increased their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, December 10th.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 3,290 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the transaction, the insider now owns 24,592 shares in the company, valued at approximately $614,800. This represents a 11.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares in the company, valued at $905,661. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,401 shares of company stock valued at $437,453 over the last quarter. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its position in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares during the last quarter. Quarry LP increased its stake in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after buying an additional 2,435 shares during the period. International Assets Investment Management LLC increased its position in Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the period. Finally, Quest Partners LLC raised its stake in Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after buying an additional 1,312 shares during the last quarter.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $20.04 on Tuesday. The firm has a market capitalization of $1.42 billion, a PE ratio of -6.89 and a beta of 2.11. The stock’s 50 day moving average price is $23.54 and its 200 day moving average price is $22.26. Nurix Therapeutics has a one year low of $7.65 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. On average, analysts forecast that Nurix Therapeutics will post -2.81 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.